Comparing the delivery of albuterol metered-dose inhaler via an adapter and spacer device in an in vitro infant ventilator lung model

Optimal delivery of aerosolized medication to mechanically ventilated pediatric and neonatal patients: A scoping review

Objectives

Delivering aerosolized medication to patients during mechanical ventilation is a common practice in respiratory therapy for adult, pediatric, and neonatal populations. However, aerosol delivery in pediatric populations is inconsistent and challenging, impacting how the drug is delivered. Some factors that influence drug delivery efficiency are directly under the purview of the clinician or therapist administering the drugs. However, excessive variability exists amongst clinicians and therapists working at the same site and between different sites. This review aims to systematically summarize the literature to identify current practice variations, identify common practices, and provide suggestions to guide future research in this area. In addition, this scoping review aims to identify the available evidence and knowledge gaps in the literature regarding the delivery of aerosolized medication to pediatric populations during mechanical ventilation. More specifically, the question that guided our research was: What are the best strategies for optimizing aerosol delivery of medication to pediatric patients, including neonates, while on mechanical ventilation?

Methods

A scoping review, using the Joanna Briggs Institute methodology, was conducted until September 2022 in the CINAHL, EMBASE (Ovid), and Medline (Ovid) databases. Our initial search yielded 248 articles. After screening the titles, abstracts, and full text of the articles according to inclusion and exclusion criteria, five articles were analyzed.

Results

We identified three main topics for discussion: the type of device used for administering aerosolized medication, appropriate mechanical ventilation settings, and optimal placement of the nebulizer delivery system.

Conclusion

Of the three topics we intended to discuss, we only found enough evidence to suggest using mesh nebulizers to increase aerosol deposition. We found conflicting or outdated results for the other two topics. This demonstrates a significant gap in the literature since aerosol medications are routinely administered to mechanically ventilated neonatal and other pediatric patients.

In vitro performance of spacers for aerosol delivery during adult mechanical ventilation

BACKGROUND

During mechanical ventilation, different aerosol generators are employed with various interfaces. The objective of this study was to evaluate the performance of a range of spacers, including a new device called Combihaler® designed for connection with both nebulizers and pressurized Metered-Dose Inhalers (pMDIs).

METHODS

To assess the spacers, we used a ventilator and the Dual Adult Training and Test Lung (model 5600i, Michigan Instruments). Ventilation parameters were measured with and without spacers in volume-controlled and pressure-controlled mode. A filter was placed at the end of the endotracheal tube to measure aerosol delivery. Amikacin (1 g/8 mL) and salbutamol (5 mg/5 mL) were nebulized with an Aeroneb Solo® connected to its T-adapter or the Combihaler® spacer. Salbutamol (100 μg/actuation with 10 actuations) and beclomethasone (250 μg/actuation with 10 actuations) were delivered with a pMDI connected to a Minispacer®, an ACE® spacer, or a Combihaler® spacer. Drug delivery measurements were performed in volume-controlled mode in dry and humidified conditions. Drug deposits on the filter were assayed.

RESULTS

The use of spacers and the T-adapter did not change the ventilation parameters (p>0.9). Aerosol delivery of salbutamol and Amikacin by nebulization increased up to three-fold with the Combihaler® compared with the T-adapter in humidified and nonhumidified conditions (p<0.05). Aerosol delivery of salbutamol and beclometasone by pMDI increased up to three-fold with the Combihaler® and the ACE® spacer compared with the Minispacer® in humidified and nonhumidified conditions (p<0.05). Aerosol delivery by pMDIs and vibrating mesh nebulizers using either a T-adapter or spacers was reduced by up to 62.5% in a humidified circuit compared with a nonhumidified circuit.

CONCLUSION

Aerosol delivery via pMDIs and vibrating mesh nebulizers is greater with large spacers (Combihaler® and ACE®) than with smaller spacers (Minispacer®) or a T-adapter, in both humidified and nonhumidified conditions. In humidified conditions, the aerosol delivery decreased with all spacers.

Evaluating the delivery of nebulized and metered-dose inhalers in an in vitro infant ventilator lung model

OBJECTIVE

To evaluate drug delivery to the lungs of nebulized and metered-dose inhalers (MDIs) in an in vitro infant lung model.

METHODS

An in vitro lung model was modified to study drug delivery. A 1000 mL intravenous bag filled with 500 mL deionized water was attached to a 3.5 mm (12 cm length) endotracheal tube. An inline Marquest Whisper Jet infant circuit nebulizer system delivered 2.5 mg/3 mL albuterol sulfate inhalation solution (Ventolin nebules) at a flow rate of 5 L/min. An Aerochamber (Monaghan) was placed at the endotracheal tube for the delivery of the MDIs. Albuterol MDI (Ventolin) 10 inhalations and beclomethasone MDI (Beclovent) 20 inhalations were delivered. A Servo 900C (Siemens-Elma) was used at the following ventilator settings: positive inspiratory pressure 30 cm H2O), intermittent mandatory ventilation 40 breaths/min, positive end expiratory pressure 4 cm H2O, inspiratory time 0.4 sec. Each formulation was run at least 10 times and assayed in duplicate by HPLC. An unpaired Student's t-test was used to analyze the statistical significance of the data.

RESULTS

There was a significantly greater percentage of drug delivery with MDI albuterol (1.96 +/- 0.50) as compared with nebulized albuterol (1.26 +/- 0.37) (p = 0.002) or beclomethasone diproprionate (0.51 +/- 0.24) (p = 0.001).

CONCLUSIONS

Albuterol MDI provides a more efficient delivery of drug to the lung as compared with nebulized albuterol and MDI beclomethasone diproprionate.